Modeling Human Digestive Diseases With CRISPR-Cas9–Modified Organoids

Masayuki Fujii, Hans Clevers, Toshiro Sato

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Insights into the stem cell niche have allowed researchers to cultivate adult tissue stem cells as organoids that display structural and phenotypic features of healthy and diseased epithelial tissues. Organoids derived from patients’ tissues are used as models of disease and to test drugs. CRISPR-Cas9 technology can be used to genetically engineer organoids for studies of monogenic diseases and cancer. We review the derivation of organoids from human gastrointestinal tissues and how CRISPR-Cas9 technology can be used to study these organoids. We discuss burgeoning technologies that are broadening our understanding of diseases of the digestive system.

Original languageEnglish
Pages (from-to)562-576
Number of pages15
JournalGastroenterology
Volume156
Issue number3
DOIs
Publication statusPublished - 2019 Feb 1

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
Organoids
Technology
Digestive System Diseases
Stem Cell Niche
Adult Stem Cells
Epithelium
Research Personnel
Pharmaceutical Preparations
Neoplasms

Keywords

  • Colorectal Cancer
  • Gastric Cancer
  • Inflammatory Bowel Disease
  • Pancreatic Cancer

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Modeling Human Digestive Diseases With CRISPR-Cas9–Modified Organoids. / Fujii, Masayuki; Clevers, Hans; Sato, Toshiro.

In: Gastroenterology, Vol. 156, No. 3, 01.02.2019, p. 562-576.

Research output: Contribution to journalReview article

Fujii, Masayuki ; Clevers, Hans ; Sato, Toshiro. / Modeling Human Digestive Diseases With CRISPR-Cas9–Modified Organoids. In: Gastroenterology. 2019 ; Vol. 156, No. 3. pp. 562-576.
@article{60abb19447674951ad7639666edc9f80,
title = "Modeling Human Digestive Diseases With CRISPR-Cas9–Modified Organoids",
abstract = "Insights into the stem cell niche have allowed researchers to cultivate adult tissue stem cells as organoids that display structural and phenotypic features of healthy and diseased epithelial tissues. Organoids derived from patients’ tissues are used as models of disease and to test drugs. CRISPR-Cas9 technology can be used to genetically engineer organoids for studies of monogenic diseases and cancer. We review the derivation of organoids from human gastrointestinal tissues and how CRISPR-Cas9 technology can be used to study these organoids. We discuss burgeoning technologies that are broadening our understanding of diseases of the digestive system.",
keywords = "Colorectal Cancer, Gastric Cancer, Inflammatory Bowel Disease, Pancreatic Cancer",
author = "Masayuki Fujii and Hans Clevers and Toshiro Sato",
year = "2019",
month = "2",
day = "1",
doi = "10.1053/j.gastro.2018.11.048",
language = "English",
volume = "156",
pages = "562--576",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Modeling Human Digestive Diseases With CRISPR-Cas9–Modified Organoids

AU - Fujii, Masayuki

AU - Clevers, Hans

AU - Sato, Toshiro

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Insights into the stem cell niche have allowed researchers to cultivate adult tissue stem cells as organoids that display structural and phenotypic features of healthy and diseased epithelial tissues. Organoids derived from patients’ tissues are used as models of disease and to test drugs. CRISPR-Cas9 technology can be used to genetically engineer organoids for studies of monogenic diseases and cancer. We review the derivation of organoids from human gastrointestinal tissues and how CRISPR-Cas9 technology can be used to study these organoids. We discuss burgeoning technologies that are broadening our understanding of diseases of the digestive system.

AB - Insights into the stem cell niche have allowed researchers to cultivate adult tissue stem cells as organoids that display structural and phenotypic features of healthy and diseased epithelial tissues. Organoids derived from patients’ tissues are used as models of disease and to test drugs. CRISPR-Cas9 technology can be used to genetically engineer organoids for studies of monogenic diseases and cancer. We review the derivation of organoids from human gastrointestinal tissues and how CRISPR-Cas9 technology can be used to study these organoids. We discuss burgeoning technologies that are broadening our understanding of diseases of the digestive system.

KW - Colorectal Cancer

KW - Gastric Cancer

KW - Inflammatory Bowel Disease

KW - Pancreatic Cancer

UR - http://www.scopus.com/inward/record.url?scp=85060989433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060989433&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2018.11.048

DO - 10.1053/j.gastro.2018.11.048

M3 - Review article

VL - 156

SP - 562

EP - 576

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 3

ER -